×

What are you searching for?




News

5 Min read

Sources suggest a surge in Cancer drugs’ share by FDA approvals

Published On 10 Sep 2019 12:33 AM


SHARE THIS ARTICLE  


Report developed by Tufts Center for the Study of Drug Development has made a comparison of FDA approved cancer drugs which have raised from 4% in the 1980s to 27% since 2010. Experts speculate this to the oncology success rate, in addition to pharmaceutical companies’ new approach to drug development which focuses mainly on cancer treatments and validation of clinical trials. Experts allege these have become better since the past. Moreov....


Tags : FDA, Cancer drugs, New cancer drugs, NTRK, BRAF, MEK, Bruton’s tyrosine kinase,
SHARE THIS ARTICLE  

Leave a comment 

comments (0)